“As some adult patients with ADHD experience insomnia, there is considerable individual variability, and an identified need for more data on the effect of prescription ADHD stimulant medications on sleep."
Many commonly prescribed drugs—such as some sleep aids—are known to carry an increased risk of breaking a bone, by increasing falls, weakening bones, or both.
Emerging research suggests the answer lies in the brain, not the airway.
The FDA says that Harmony Biosciences’ drug—previously approved for excessive daytime sleepiness in narcolepsy—works for cataplexy too. Harmony’s chief medical officer explains how this impacts healthcare practitioners and patients.
Read More
Results of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More
FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on two randomized, controlled trials.
Read More
Though men and women can have different responses to medications—Ambien, for example, metabolizes more slowly in women, causing next-day grogginess—doctors may not know about these differences because most clinical trial data are biased toward men.
Read More
Benzodiazepines are ‘commonly abused and misused, often together with opioid pain relievers and other medicines, alcohol, and illicit drugs.’
Read More
The GABAA receptor is particularly sensitive to its surrounding environment and has the ability to change conformation in different ways based on the binding of different drugs.
Read More
The FDA approved a new oxybate formulation for excessive daytime sleepiness or cataplexy in narcolepsy. Should your patients switch?
Read More
A registry study involving 2 million pregnant women shows no association between modafinil and an increased risk of malformation in babies.
Read MoreHighlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read MoreThe data include a final analysis of the Pitolisant Expanded Access Clinical Evaluation Program, two post-hoc analyses on clinically relevant outcomes from the Phase 3 clinical trials, and analyses that further characterize the cardiac safety profile of WAKIX.
Read MoreHighlights include an oral presentation focusing on the long-term efficacy and safety of DAYVIGO in adults ages 65 and older with insomnia disorder from the Phase 3 clinical study.
Read More
New findings confirm the persistence of a drug dose gender gap stemming from a historic disregard of the biological differences between male and female bodies.
Read More
Patients are vulnerable in the period after discharge, when risks and adverse reactions can result in ER visits, rehospitalization, and even death within 30 days.
Read More
A new study finds about 20% of restless legs syndrome patients are prescribed doses above the recommended maximum.
Read More
DAYVIGO targets orexin receptors to facilitate sleep. It’s been trialed in the elderly and in patients with common comorbidities.
Read More